Cancer
Malignant Kidney Neoplasm
CI-CAN-00003171Explore in graph →
Top-level453 active trials17 approved drugs80 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003171Explore in graph →
Clinical trials
2,143 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (339)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00335556 | Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors | completed | Phase 2 | 291 | Children's Oncology GroupNETWORK | 5 | Jul 21, 2017 | clinicaltrials |
| NCT00496587 | Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT01176500 | A Pilot, Open-label Study of 18F-Fluciclatide PET/CT Imaging in the Evaluation of Anti-angiogenic Therapy in Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00357760 | Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 2 | Jun 23, 2017 | clinicaltrials |
| NCT02883153 | Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma | completed | Phase 2 / Phase 3 | 30 | Radboud University Medical CenterOTHER | 1 | Jun 19, 2017 | clinicaltrials |
| NCT00934440 | A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma(5-AZ) | terminated | Phase 1 / Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT01189370 | Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer | completed | Phase 2 | 25 | University of Kansas Medical CenterOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT00376987 | Zinc Supplements in Lowering Cadmium Levels in Smokers | completed | Phase 2 | 61 | Wake Forest University Health SciencesOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00534001 | Bupropion in Helping Adults Stop Smoking | completed | Phase 2 | 95 | Roswell Park Cancer InstituteOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT00835978 | Axitinib (AG-013736) With Or Without Dose Titration (Increase) In Patients With Kidney Cancer | completed | Phase 2 | 213 | PfizerINDUSTRY | 6 | May 30, 2017 | clinicaltrials |
| NCT01462214 | Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer | completed | Phase 1 / Phase 2 | 96 | Hans J. van der Vliet, MD, PhDOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT02330783 | Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients | unknown | Phase 2 | 106 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 9, 2017 | clinicaltrials |
| NCT00425386 | Sunitinib and Erlotinib in Treating Patients With Unresectable or Metastatic Kidney Cancer | completed | Phase 2 | 60 | OHSU Knight Cancer InstituteOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00401128 | Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 9 | The Cleveland ClinicOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT00184015 | Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC) | unknown | Phase 1 / Phase 2 | 50 | University of Southern CaliforniaOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT00651482 | Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) | terminated | Phase 2 | 10 | Sandy SrinivasOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT00971620 | Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT02071641 | Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 5 | Amsterdam UMC, location VUmcOTHER | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 2 | 14 | University of ArizonaOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00244764 | GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma | completed | Phase 2 | 225 | GlaxoSmithKlineINDUSTRY | 8 | Mar 27, 2017 | clinicaltrials |
| NCT00467077 | Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer | terminated | Phase 2 | 21 | California Cancer ConsortiumNETWORK | 1 | Mar 17, 2017 | clinicaltrials |
| NCT00630409 | Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma | completed | Phase 2 | 5 | University of PittsburghOTHER | 1 | Mar 10, 2017 | clinicaltrials |
| NCT01141569 | A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2017 | clinicaltrials |
| NCT00617253 | Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients | completed | Phase 2 | 9 | Novo Nordisk A/SINDUSTRY | 2 | Mar 1, 2017 | clinicaltrials |
| NCT02607553 | Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA | completed | Phase 2 | 2 | GenSpera, Inc.INDUSTRY | 1 | Feb 24, 2017 | clinicaltrials |
| NCT01264341 | Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma | terminated | Phase 2 | 39 | Hellenic Cooperative Oncology GroupOTHER | 1 | Feb 14, 2017 | clinicaltrials |
| NCT03047525 | Study of DC-CTL Combined With CIK for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 200 | Xiaoyi HuangOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT01441765 | PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine | terminated | Phase 2 | 11 | Beth Israel Deaconess Medical CenterOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT00423332 | Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma | completed | Phase 2 | 105 | AstraZenecaINDUSTRY | 2 | Feb 2, 2017 | clinicaltrials |
| NCT00003657 | High-dose ICE With Amifostine | completed | Phase 2 | 24 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 20, 2017 | clinicaltrials |
| NCT00256880 | Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma | completed | Phase 2 | 100 | GlaxoSmithKlineINDUSTRY | 2 | Jan 18, 2017 | clinicaltrials |
| NCT02446795 | Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial(QUASAR) | unknown | Phase 1 / Phase 2 | 104 | Consorzio OncotechOTHER | 1 | Jan 18, 2017 | clinicaltrials |
| NCT00550654 | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain | terminated | Phase 2 | 1 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jan 13, 2017 | clinicaltrials |
| NCT00672178 | Stereotactic Body Radiotherapy (SBRT) and Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer (RCC) | terminated | Phase 1 / Phase 2 | 1 | Duke UniversityOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT01712685 | Imaging Studies of Kidney Cancer Using 18F-VM4-037 | terminated | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02334709 | Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect. | completed | Phase 1 / Phase 2 | 13 | University Hospital, GhentOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT02829775 | A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies | completed | Phase 2 / Phase 3 | 9 | Hoffmann-La RocheINDUSTRY | 7 | Jan 9, 2017 | clinicaltrials |
| NCT00903175 | Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma(RECORD-3) | completed | Phase 2 | 471 | Novartis PharmaceuticalsINDUSTRY | 19 | Nov 8, 2016 | clinicaltrials |
| NCT02828709 | Safety and Feasibility of IRE for SRMs | unknown | Phase 2 | 20 | Dr. Prof. M.P. Laguna PesOTHER | 1 | Sep 27, 2016 | clinicaltrials |
| NCT00126594 | Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2016 | clinicaltrials |
| NCT00365768 | Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors | completed | Phase 2 | 56 | Columbia UniversityOTHER | 1 | Sep 9, 2016 | clinicaltrials |
| NCT02886897 | A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Sep 1, 2016 | clinicaltrials |
| NCT01442090 | Study of GDC-0980 Versus Everolimus in Participants With Metastatic Renal Cell Carcinoma Who Have Progressed on or Following Vascular Endothelial Growth Factor- (VEGF) Targeted Therapy | completed | Phase 2 | 85 | Genentech, Inc.INDUSTRY | 5 | Aug 10, 2016 | clinicaltrials |
| NCT00318110 | Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma | terminated | Phase 2 | 4 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jul 26, 2016 | clinicaltrials |
| NCT00027573 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 2 | 36 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT00042965 | Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 60 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 14, 2016 | clinicaltrials |
| NCT00006483 | Sargramostim in Treating Patients With Kidney Cancer That Has Spread to the Lung | completed | Phase 2 | 27 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 13, 2016 | clinicaltrials |
| NCT00465179 | Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer | completed | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 7, 2016 | clinicaltrials |
| NCT01491672 | Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma(RECORD-4) | completed | Phase 2 | 134 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 6, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jul 21, 2017source: clinicaltrials